Estradiol/norethisterone-transdermal - Fournier Pharma

Drug Profile

Estradiol/norethisterone-transdermal - Fournier Pharma

Alternative Names: norethisterone/estradiol-transdermal; Norethisterone/estradiol-transdermal - Fournier Pharma; TS 20c

Latest Information Update: 30 Mar 2001

Price : $50

At a glance

  • Originator Fournier Pharma
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 30 Mar 2001 Discontinued-I for Menopausal syndrome in France (Transdermal)
  • 30 Mar 2001 Discontinued-I for Postmenopausal osteoporosis in France (Transdermal)
  • 21 Jun 2000 Ares-Serono is now called Serono
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top